A human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line and its establishment method and application

A technology of epidermal growth factor and tyrosine kinase, which is applied in the field of human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line and its establishment, which can solve the problem of drug-resistant cell lines failing to respond to drug resistance mechanisms, tumor Difficult tissue acquisition, poor stability of biological properties of drug-resistant cell lines, etc., to achieve the effect of easy acquisition, stable biological properties, and enriched cell banks

Active Publication Date: 2021-09-28
SHANGHAI PULMONARY HOSPITAL
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The present invention is mainly aimed at the technical problem that the tumor tissue is not easy to obtain in the primary culture of lung cancer cell lines, the problem that the drug-resistant cell line induced by the current method cannot reflect the real drug resistance mechanism, and the biological characteristics of the drug-resistant cell line The problem of poor stability provides a new human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line and its establishment method and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line and its establishment method and application
  • A human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line and its establishment method and application
  • A human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line and its establishment method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] 1 Experimental materials

[0036]DMEM medium: purchased from HyClone Company;

[0037] Fetal bovine serum (FBS) is a product of GIBCO;

[0038] BALB / c-nu mice: purchased from Shanghai Slack Experimental Animal Co., Ltd.;

[0039] Gefitinib API: purchased from Dalian Meilun Biotechnology Co., Ltd.;

[0040] Matrigel: purchased from Corning;

[0041] Other sources of reagents are:

[0042]

[0043] 2 Experimental methods

[0044] Among the inpatients in Shanghai Pulmonary Hospital, looking for lung cancer patients with acquired drug resistance after one year of oral gefitinib treatment, extract 400-500ml of pleural effusion (non-small cell lung cancer cells found in pleural effusion: adenocarcinoma), room temperature Settling for 1 hour. The precipitate was collected, centrifuged at 1500 rpm for 10 min, and the supernatant was carefully removed. Add PBS, centrifuge at 1500rpm for 10min and wash three times. Take a small amount of precipitate and smear it on a g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to view more

Abstract

The invention relates to a human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line and its establishment method and application. The present invention collects and confirms the sediment containing cancer cells from the pleural effusion of lung cancer patients with acquired resistance to human epidermal growth factor tyrosine kinase inhibitors, cultures them in vitro and inoculates them in the armpit of mice, and takes tumor tissues after tumor formation. Primary culture, and then confirm that the purity of tumor cells > 90% is drug-resistant tumor cells, and obtain human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line, the preservation number is CCTCC NO: C2018121, the cell line is reserved The main clinical biological characteristics can be more truly reflected drug resistance mechanism, high tumor formation rate, stable biological properties, strong vitality, is an ideal human epidermal growth factor tyrosine kinase inhibitor acquired drug resistance Cell line material for basic research and preclinical testing.

Description

technical field [0001] The invention relates to the technical field of drug-resistant cell lines, in particular to a human epidermal growth factor tyrosine kinase inhibitor acquired drug-resistant lung cancer cell line and its establishment method and application. Background technique [0002] In recent years, with the development of modern industry, the deterioration of people's living environment, the impact of bad living habits and the aging population, the incidence of lung cancer has increased year by year. In 2016, CA Cancer J Clin published the 2015 cancer statistics in China. In 2015, there were about 733,300 new lung cancer cases in my country, ranking first among the top ten tumors in terms of incidence and mortality. Although the level of diagnosis and treatment of lung cancer has been greatly improved compared with the past, lung cancer is still one of the malignant tumors with the highest mortality rate, and the 5-year survival rate of lung cancer is only 16.1%....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/09C12Q1/02
CPCC12N5/0693C12N2509/00G01N33/5017G01N33/5044
Inventor 周崧雯邓沁芳谢博雄季现秀方启宇孙辉鲍昱辰
Owner SHANGHAI PULMONARY HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap